TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo

Abstract

Iron chelation therapy is an effective approach to the treatment of iron overload conditions, in which iron builds up to toxic levels in the body and may cause organ damage. Treatments using deferoxamine, deferasirox and deferiprone have been introduced and despite their disadvantages, they remain the first-line therapeutics in iron chelation therapy. Our study aimed to compare the effectiveness of the iron chelation agent TLc-A, a nano chelator synthetized based on the novel nanochelating technology, with deferoxamine. We found that TLc-A reduced iron overload in Caco2 cell line more efficiently than deferoxamine. In rats with iron overload, very low concentrations of TLc-A lowered serum iron level after only three injections of the nanochelator, while deferoxamine was unable to reduce iron level after the same number of injections. Compared with deferoxamine, TLc-A significantly increased urinary iron excretion and reduced hepatic iron content. The toxicity study showed that the intraperitoneal median lethal dose for TLc-A was at least two times higher than that for deferoxamine. In conclusion, our in vitro and in vivo studies indicate that the novel nano chelator compound, TLc-A, offers superior performance in iron reduction than the commercially available and widely used deferoxamine.

An Investigation on the Effect of BCc1 Nanomedicine on Gastric Cancer Patients Using EORTC QLQ-STO30 Questionnaire

“…Nanochelating technology, as a new method, has proved to have a significant impact on the treatment of various diseases by synthesizing different nanostructures with effective properties, using controlled self-assembly methods (23)(24)(25). For instance, BCc1 nanomedicine with chelating properties and dominant affinity for iron elements have high potentials to induce therapeutic behavior for the treatment of cancer (26).…”

Knockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy

“…In tumors, the leaky vasculature system allows higher delivery of the nano-drugs and therefore less cytotoxicity to the normal tissues (23). Hafizi et al synthesized the nanoparticle BCc1 based on a novel nanochelating technology (24)(25)(26) and confirmed its high affinity to iron. By chelating the iron ions, BCc1 reduces the activity of the iron-dependent ribonucleotide reductase which is required for DNA synthesis and cell proliferation.…”

<p>DIBc, a nanochelating-based nano metal-organic framework, shows anti-diabetic effects in high-fat diet and streptozotocin-induced diabetic rats</p>

“…In the previous studies, therapeutic aspects of nanochelating-based structures were evaluated in vitro and in vivo. [12][13][14][15] In the current study, we assessed the effects of DIBc, a nanochelating-based NMOF on highfat diet and streptozotocin (STZ)-induced diabetic rats. 16,17 According to the beneficial effects of selenium, zinc, and chromium supplementation on diabetic patients and also diabetic animal models, the NMOF structure contained these elements.…”